Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) has issued a postal ballot notice dated May 14, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, seeking approval of its members on five special business resolutions. These resolutions cover the appointment and remuneration of Mr. Umang Vohra as Chairman and Group Chief Executive Officer, as well as the introduction and extension of the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' (ESOP 2026). The remote e-voting facility, provided by KFin Technologies Limited (KFinTech), is open from Friday, May 15, 2026 at 9:00 a.m. (IST) to Saturday, June 13, 2026 at 5:00 p.m. (IST), with voting results to be declared on or before Monday, June 15, 2026.

Appointment of Mr. Umang Vohra as Chairman and Group CEO

The Board of Directors, on the recommendation of the Nomination and Remuneration Committee (NRC), at their meeting held on 27 April 2026, appointed Mr. Umang Vohra (DIN: 02296740) as additional director, designated as Chairman with effect from the opening business hours of 1 May 2026 and as Group Chief Executive Officer with effect from the opening business hours of 20 May 2026, in each case until 30 April 2031, subject to member approval. Mr. Vohra holds a bachelor's degree in engineering (Computer Science) from M.S. Ramaiah Institute of Technology and a Master of Business Administration from T.A. Pai Management Institute. He brings over 30 years of experience in the pharmaceutical sector, having served as Managing Director and Global CEO of Cipla Limited for a decade, and prior to that, spent over 14 years at Dr. Reddy's Laboratories as CFO and Head of North America Generics. Earlier in his career, he was also associated with PepsiCo India.

The key details of Mr. Vohra's profile are summarised below:

Remuneration Structure

The proposed remuneration for Mr. Vohra, benchmarked against industry peers of comparable and larger sizes, comprises fixed compensation, variable compensation, employee stock options (ESOPs), and perquisites. The remuneration may exceed the limits prescribed under Section 197 of the Companies Act, 2013, for which a special resolution is being sought. Central Government approval is also required solely on account of Mr. Vohra being a non-resident.

The key components of Mr. Vohra's proposed remuneration are as follows:

For reference, Mr. Vohra's remuneration from his previous role at Cipla Limited in FY 24-25 was as follows:

ESOP 2026: Key Features and Dilution Structure

The Board approved the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' (ESOP 2026) at its meeting held on 27 April 2026, subject to member approval. The plan covers up to 2,59,18,613 (two crore fifty nine lakhs eighteen thousand six hundred and thirteen) equity shares of face value INR 1/- each, representing 6.25% of the fully diluted equity share capital. The ESOP 2026 will be implemented directly by the Company through fresh issue of shares, under the superintendence of the Nomination and Remuneration Committee.

The aggregate dilution on account of ESOP 2023 and ESOP 2026 is set out below:

Key vesting and exercise parameters of the ESOP 2026 include:

• Vesting period: Minimum 1 year, maximum 8 years from the date of grant
• Exercise period: Up to 3 years from the date of vesting
• Exercise price: Not less than INR 325 per share for grants made within 6 months of in-principle stock exchange approval
• Time-vested grants: Shall not exceed 37% of total grants under ESOP 2023 and ESOP 2026 in aggregate
• Performance-based vesting: Subject to company-level parameters including growth in revenue and EBITDA, customer base expansion, operational metrics, quality metrics, and share price targets (at least INR 650)

The performance vesting schedule is as follows:

Company Financial Performance

The consolidated financial performance of the Company, as referenced in the postal ballot notice, is summarised below (in INR Crores):

E-Voting Process and Timeline

The postal ballot notice has been sent electronically to members whose names appear on the Register of Members as on the cut-off date of May 8, 2026. The e-voting event number (EVEN) is 9708. Members may cast their votes through the KFinTech e-voting platform at https://evoting.kfintech.com . The scrutiniser appointed for the process is Mr. DVM Gopal (Membership No. F6280 and COP No. 6798), Partner, M/s. DVM & Associates LLP, Company Secretaries. Results will be communicated to BSE Limited and the National Stock Exchange of India Limited and displayed on the Company's website at www.cohance.com on or before Monday, June 15, 2026. Members with e-voting grievances may contact KFin Technologies Limited at evoting@kfintech.com or call toll-free at 1800-309-4001.

Source: None/Company/INE03QK01018/e479290882614f0a.pdf

Cohance Lifesciences Limited has informed the stock exchanges that its management will participate in upcoming analyst and institutional investor meetings. These interactions are scheduled to take place in May 2026.

Conference Schedule

The company management will attend the following conferences to engage with investors and analysts. The schedule is subject to change based on exigencies.

Disclosure Compliance

The company stated that no unpublished price-sensitive information will be shared during these interactions. The intimation was submitted to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.